The COVID chapter has been updated, overhauled, and refocused on the management of the sickest COVID patients (those requiring admission to ICU or stepdown units). The new chapter removes more basic information about COVID that we're all probably familiar with at this point (but the original, larger chapter is still available here).
The goal of the new chapter is to provide an easily readable and up-to-date approach to the sickest COVID patients. This is obviously a work in progress, which will continue to be updated based on continually emerging information.
A fresh overview podcast will be out really soon, so stay tuned for that.
-
The IBCC chapter is located 👉 here.
- The podcast & comments are below.
Follow us on iTunes
Josh is the creator of PulmCrit.org. He is an associate professor of Pulmonary and Critical Care Medicine at the University of Vermont.
Latest posts by Josh Farkas (see all)
- IBCC – Hepatorenal Syndrome - February 22, 2021
- IBCC – Coagulation management in cirrhosis - February 15, 2021
- PulmCrit – RECOVERY confirms benefit of toci combined with dexamethasone - February 12, 2021
I wish you could have talked about anticoagulation.
Quick text from Lisbon, most of our ICUs have reached capacity so patients are arriving later to ICU. Still, any thoughts on the drawbacks of standard dexamethsone treatment for hypoxaemic patients? We are seeing an increase in VAP. More likely reflets pateints being admitted later and sicker and ICU being swamped and continuously expanding its capacity etc but wondering if anyone else is experiencing the same.
here is much more data info from the recently released RCT on anticoagulation – https://nhlbi-connects.org/documents/mpRCT%20Interim%20Presentation.pdf
Bravo thank you sir for all your hard work. Your dedication to medical education is truly respectable.